Are 'plat­form plays' here to stay?; The Aduhelm saga con­tin­ues to un­fold; A new GSK?; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

End­points News turned five years old last week­end! Long­time read­ers would see how far we’ve come, and it’s all thanks to you, our sub­scribers. If you en­joy our cov­er­age, please read pub­lish­er Ar­salan Arif’s note on how you can sup­port us for the next phase of growth.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA